Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lexaria Bioscience Corp (LEXX)

Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Lexaria (NASDAQ: LEXX) Grows Patent Portfolio to 41; Maintains Focus on GLP-1 Clinical Studies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, in the month of April 2024, added three new patents to its portfolio. This brings the total number of awarded patents globally...

LEXX : 2.15 (-4.44%)
Lexaria Bioscience (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the appointment of Nelson Cabatuan, CPA, as its new Chief Financial Officer (“CFO”). Nelson will...

LEXX : 2.15 (-4.44%)
Lexaria Bioscience (NASDAQ: LEXX) Focusing on GLP-1 Applications of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that it will focus on glucagon-like peptide 1 (“GLP-1”) applications of its patented DehydraTECH(TM)...

LEXXW : 1.0100 (+32.89%)
LEXX : 2.15 (-4.44%)
Lexaria (NASDAQ: LEXX) Hires Research Organization to Perform GLP-1 Human Pilot Study

At the beginning of the year, Lexaria Bioscience (NASDAQ: LEXX), a global innovator for enhanced drug delivery platforms, announced its intention to double down on GLP-1 clinical studies for the 2024 calendar...

LEXX : 2.15 (-4.44%)
Lexaria (NASDAQ: LEXX) CEO to Present at the Upcoming 14th Annual LD Micro Invitational

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced that it will be participating at the 14th Annual LD Micro Invitational at the Sofitel New York on...

LEXX : 2.15 (-4.44%)
LEXXW : 1.0100 (+32.89%)
Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Achieves 7% Weight Loss

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released highlights from its DIAB-A22-1 animal study on rodents. The study sought to explore the overall efficiency...

LEXX : 2.15 (-4.44%)
Lexaria to Present at The LD Micro Invitational XIV

Kelowna, British Columbia--(Newsfile Corp. - March 21, 2024) - Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces...

LEXX : 2.15 (-4.44%)
Lexaria (NASDAQ: LEXX) Marks 2024 Milestone with FDA Clearance for Planned U.S. Phase 1b Hypertension Trial

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that the U.S. Food and Drug Administration (“FDA”) has given it the requisite clearance to proceed with...

LEXX : 2.15 (-4.44%)
Lexaria Bioscience (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has appointed a new chief financial officer. The company announced that, effective immediately, Nelson Cabatuan,...

LEXX : 2.15 (-4.44%)
LEXXW : 1.0100 (+32.89%)
Lexaria Bioscience (NASDAQ: LEXX) Banking on DehydraTECH(TM) for Major 2024 Growth

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has been pushing the envelope and redefining drug delivery technology. Its patented DehydraTECH(TM) technology has proven...

LEXX : 2.15 (-4.44%)

Barchart Exclusives

Up 67% YTD, Is Soundhound AI Overvalued?
Soundhound AI's shares have surged, thanks to Nvidia's investment in the company and growing enthusiasm surrounding AI. After a steep pullback, is the stock still overvalued? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar